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Abstract
Although the vast majority of patients with a myelodysplastic syndrome (MDS) suffer from
cytopenias, the bone marrow is usually normocellular or hypercellular. Apoptosis of hemato-
poietic cells in the bone marrow has been implicated in this phenomenon. However, in MDS
it remains only partially elucidated which genes are involved in this process and which
hematopoietic cells are mainly affected. We employed sensitive real-time PCR technology
to study 93 apoptosis-related genes and gene families in sorted immature CD34+ and the
differentiating erythroid (CD71+) and monomyeloid (CD13/33+) bone marrow cells. Unsu-
pervised cluster analysis of the expression signature readily distinguished the different cellu-
lar bone marrow fractions (CD34+, CD71+ and CD13/33+) from each other, but did not
discriminate patients from healthy controls. When individual genes were regarded, several
were found to be differentially expressed between patients and controls. Particularly, strong
over-expression of BIK (BCL2-interacting killer) was observed in erythroid progenitor cells
of low- and high-risk MDS patients (both p = 0.001) and TNFRSF4 (tumor necrosis factor
receptor superfamily 4) was down-regulated in immature hematopoietic cells (p = 0.0023) of
low-risk MDS patients compared to healthy bone marrow.
Introduction
Myelodysplastic syndromes (MDS) represent a heterogeneous group of malignant hematopoi-
etic disorders that are characterized by dysplasia in the myeloid, megakaryocytic and/or ery-
throid cell lineages. The clinical course of MDS is highly variable. Whereas some patients
suffer from smoldering cytopenias, others rapidly develop a more aggressive disease eventually
resulting in acute myeloid leukemia (AML). The WHO classification and International Prog-
nostic Scoring systems (IPSS and IPSS-R) recognize the heterogeneity of MDS and divide
PLOS ONE | DOI:10.1371/journal.pone.0165582 November 30, 2016 1 / 11
a11111
OPENACCESS
Citation: Langemeijer SMC, Mariani N, Knops R,
Gilissen C, Woestenenk R, de Witte T, et al. (2016)
Apoptosis-Related Gene Expression Profiling in
Hematopoietic Cell Fractions of MDS Patients.
PLoS ONE 11(11): e0165582. doi:10.1371/journal.
pone.0165582
Editor: Louise Purton, St. Vincent’s Institute,
AUSTRALIA
Received: May 17, 2016
Accepted: October 16, 2016
Published: November 30, 2016
Copyright: © 2016 Langemeijer et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Complete data are
retrievable on Gene Expression Omnibus with the
accession number GSE89579.
Funding: This work was supported by grants from
the "Dutch Organization for Scientific Research"
(NWO, 92003420) to SMCL and the "Dutch Cancer
Society" (KWF) to NM. The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
patients into subgroups based on characteristics such as the amount of blasts in the bone mar-
row and the number of cytopenias [1–4].
Although cytopenias are present in the peripheral blood of the vast majority of MDS
patients, the bone marrow is usually normocellular or hypercellular. Apoptosis of hematopoi-
etic cells in the bone marrow has been implicated in this phenomenon. Several studies have
shown signs of increased apoptosis in bone marrow of MDS patients, using techniques such as
in situ end labeling (ISEL) of fragmented DNA/ TUNEL assay [5–7], electron microscopy [8,
9], flowcytometry using annexin V staining [10–12] and measurement of mitochondrial mem-
brane potential [11]. The percentage of cells affected by apoptosis differs between studies, pos-
sibly due to the use of different techniques and the heterogeneity of the clinical samples
studied. In most, but not all studies apoptosis markers are particularly elevated in the more
indolent cases of MDS, whereas apoptosis is reduced or at normal levels in the more aggressive
cases. This led to the hypothesis that apoptosis is initially increased in MDS due to either pri-
mary defects of the apoptotic pathway or in response to oncogenic stress. During the advanced
stages of MDS, this response may be lost as a result of further transformation of the malignant
cells. The presence of apoptosis has been studied in whole bone marrow and in several bone
marrow fractions, such as CD34+ cells. Depending on the study, increased apoptosis parame-
ters were found in the CD34+ cell fraction of all MDS patients [11, 12] or only in patients with
the more indolent phenotype [10]. Others described that apoptosis is mainly increased in the
more committed myeloid, erythroid and/or megakaryocytic lineages [8, 12, 13].
Apoptosis is a tightly regulated process that involves many proteins. The differential regula-
tion of some of these proteins, such as Fas [12, 14], FLIP [13, 15], BCL-2 and BCL-2-related
proteins [10, 16–21], TNF proteins and their receptors [22–25], IAPs [7, 26–28] and caspases
[19, 29–32] has been the subject of studies in MDS patients. Most of these studies focused on
only one or a few apoptosis-related genes and were performed in either whole bone marrow or
the CD34+ cell fraction. Based on the results of these previous studies, we hypothesized that a
distinct apoptotic gene expression signature might be present in specific hematopoietic stem
and progenitor fractions from healthy individuals compared to MDS patients. To gain insight
into the expression patterns of apoptosis-related genes, we have employed sensitive real-time
PCR technology to study 93 apoptosis-related genes and gene families in both CD34+ imma-
ture hematopoietic cells as well as differentiated erythroid (CD71+) and monomyeloid
(CD13/33+) cells.
Results
Isolation of hematopoietic cell fractions
Hematopoietic cell fractions were isolated from the bone marrow of 23 patients and 10 healthy
controls (S1 Table). Three different hematopoietic cell fractions were sorted, CD34+ cells
(immature hematopoietic cells), CD71+ erythroid precursors and CD13/33+ mono-myeloid
precursors. According to the IPSS score 4 low, 11 int-1, 4 int-2 and 4 high risk patients were
included. In most cases we were able to isolate all three subfractions from the same patient (S1
Table). As a control, the expression of several genes related to erythroid differentiation (TFRC,
GYPA, GYPB, GYPC, SPTB, SPTA1, EBP41, EBP42 and HBB) was measured in all fractions
and shown to be highly upregulated in CD71+ cells (data not shown).
Unsupervised cluster analysis separates different bone marrow fractions
but does not differentiate MDS patients and controls
Unsupervised hierarchical cluster analysis was performed based on the expression of 93 apo-
ptosis-related genes. These included members of the TNF (Receptor) Family, BCL-2 Family,
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IAPs, Caspases, CARD Family, TRAF family and others (S2 Table). The analysis showed a
clear clustering of the three hematopoietic cell fractions, indicating different patterns of apo-
ptosis-related gene activity in these cell fractions (Fig 1). Unexpectedly, within each cell frac-
tion, patients and healthy controls could not be distinguished based on the global expression
pattern of these apoptosis-related genes (Fig 1). Also low-risk MDS and high-risk MDS patient
groups could not be distinguished using this approach.
Differential expression of apoptosis-related genes in MDS patients and
controls
Analysis of individual genes revealed several genes that were differentially expressed between
patients and controls in more than one cell fraction: BIK, TNFRSF19 and TNFRSF7 (CD34
+ and CD71+ fractions) and MDM2 (CD71+ and CD13/33+ fractions) (Tables 1, 2 and 3,
Fig 1. Unsupervised hierarchical cluster analysis of all samples based on apoptosis-related gene
expression profile. Cell fractions are shown in the first column: CD34+ cells (blue), CD71+ cells (green),
CD13/33+ cells (red). The second column shows patients and controls: controls (purple), low risk MDS (light
blue), high risk MDS (orange).
doi:10.1371/journal.pone.0165582.g001
Table 1. Differentially expressed genes in the CD34+ cell fraction in MDS patients versus controls.
Gene p-value effect on apoptosis Ratio of median expression in patients/ controls
TNFRSF19 0.006 pro 0.2
TNFRSF7 0.013 pro 0.1
BIK 0.016 pro 0.6
RIPK2 0.020 pro 1.5
CARD11 0.035 pro 0.6
RALBP1 0.047 anti 2.9
doi:10.1371/journal.pone.0165582.t001
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Fig 2). Of these genes, only the pro-apoptotic BIK gene showed a significantly increased
expression after correction of p-values for multiple testing. The analyses were repeated after
the MDS patients were divided into low-risk and high-risk groups. As was the case for the
comparison between all patients and controls, differential expression was detected of
TNFRSF4,TNFRSF19,RALBP1 and TNFRSF7 in the CD34+ fraction, BIK, DAPK1, DAPK2,
BNIPL, TNFSRF10A, and CARD9 in the CD71+ group and TNFSRF13B,MDM2, DAPK2,
TNFRSF10C, and CARD6 in the CD13/33+ fraction. In addition, several other genes mainly
showed differences in expression between the low-risk and high-risk MDS patients and not
between patients and controls (S3 Table). TNFRSF4 and BIK showed the most prominent dif-
ferences in expression between the different patient groups and controls. BIK was expressed
more than 200-fold higher in CD71+ cells of both low-risk MDS and high-risk MDS compared
to healthy controls (p = 0.003). TNFRSF4 displayed a marked down-regulation in CD34+ cells
of low-risk MDS patients compared to controls, and a significant increase of expression in
high-risk MDS CD71+ cells compared to low-risk MDS CD71+ (p = 0.0023).
Discussion
We have studied the expression of a large set of genes and gene families that have been associ-
ated with apoptosis in three different FACS isolated hematopoietic cell fractions from MDS
patients and healthy controls. Using sensitive real-time PCR analysis followed by unsupervised
clustering analysis of the measured gene expression levels, we were able to distinguish the
Table 2. Differentially expressed genes in the CD71+ cell fraction in MDS patients versus controls.
Gene p-value effect on apoptosis Ratio of median expression in patients/ controls
BIK 0.001* pro 203
BNIPL 0.004 pro 0.1
DAPK1 0.020 pro 3.6
BBC3 0.015 pro 3.0
EDA2R 0.015 pro 49
TNFRSF10A 0.015 pro 3.9
CARD9 0.018 pro 1.6
CASP9 0.018 pro 7.0
DAPK1 0.012 pro 3.3
MDM2 0.020 anti 1.8
TNFSRF19 0.020 pro 0.2
TNFRSF7 0.022 pro 0.2
TNFRSF10B 0.028 pro 6.2
BCL2L10 0.032 anti 2.1
BAG3 0.035 anti 3.1
TNFRSF10D 0.044 anti 2.9
*indicates significant difference (p<0.05) using p-value for multiple testing
doi:10.1371/journal.pone.0165582.t002
Table 3. Differentially expressed genes in the CD13/33+ cell fraction in MDS patients versus controls.
Gene p-value effect on apoptosis Ratio of median expression in patients/ controls
MDM2 0.004 anti 1.7
TNFRSF13B 0.005 - 0.01
FADD 0.035 pro 1.7
doi:10.1371/journal.pone.0165582.t003
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CD34+, CD71+ and CD13/33+ cell fractions. Unexpectedly, global patterns of gene expression
could not distinguish healthy controls and low risk and high risk MDS patients, but consis-
tently clustered the different cellular subsets. Gene expression analysis has been shown to be a
powerful tool for patient stratification, discovery of cancer subtypes, and prediction of survival
[33–40]. Although our cohort is relatively small, our results suggest that the apoptotic pathway
is not grossly deregulated at the transcriptional level in MDS. Analysis of the expression of sin-
gle genes identified a limited number of genes that were differentially expressed between these
groups. Deregulation of the expression of some of these genes has been implicated in MDS
before. Increased expression of TNFRSF10A (TRAIL-R1) in MDS has been described, though
not specifically in the CD71+ population [23]. Differential expression of other genes, such as
TP53 and BCL2, that have previously been implicated in MDS, could not be confirmed in our
study. Differences between our study and those of others could be due to the bone marrow
fractions studied and the selection of patients. The BIK (BCL-2 interacting killer) gene showed
the most prominent increased expression in CD71+ in MDS patients compared to controls.
BIK is a pro-apoptotic BH3-only member of the Bcl-2 family [41]. Its binding to Bcl-2 pro-
motes apoptosis [42] and such binding is elicited through several pathways, most notably
TP53 [43], E2F1 [44], Smad [45], and miR608 [46]. BIK is normally undetectable or expressed
at low levels in cancers [47–50] but specific tumors that were marked with high BIK expression
have been targeted for induction of apoptosis leading to tumor reduction [51–54]. BIK has
been found to be over-expressed in 14 out of 15 breast cancer samples [47], and was also pres-
ent in a gene expression signature consisting of 64 genes that correlated with long-term sur-
vival in non-small cell lung cancer patients [55]. Although mutations in BIK have been found
in B-cell lymphomas [56], little is known about the role of BIK in hematopoietic malignancies.
In acute myeloid leukemia, BIK was found to be upregulated in the leukemic cells compared to
controls [57]. In addition, it has recently been observed that BIK is involved in autophagy in
cancer cells [58, 59]. Although the role of autophagy in myeloid malignancies is still largely
unclear [60], autophagy inhibitors are currently being tested in clinical trials [61, 62]. The out-
standing over-expression of BIK in MDS CD71+ cells is a novel finding, and since BIK is pro-
apoptotic, its overexpression in MDS CD71+ cells might be involved in increased cell death,
particularly in the CD71+ erythroid cells in MDS.
Fig 2. Expression of BIK in MDS patients and controls. BIK expression in ‘low risk’ patients, ‘high risk’
patients and controls. The expression of BIK is depicted relative to the housekeeping gene GAPDH. Median
level of expression is indicated.
doi:10.1371/journal.pone.0165582.g002
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The only other gene that maintained significance after correction for multiple testing was
TNFRSF4, which we found to be down-regulated in CD34+ cells of low risk MDS patients.
TNFRSF4, also known as OX40 or CD134, is mainly known for its role in T-cells. Upon activa-
tion it promotes cell survival and clonal expansion [63], and the secretion of pro-inflammatory
cytokines, mainly IL-2 [64]. TNFRSF4 has been suggested as a potential target for immuno-
therapy [65–67] [68]. Little is known of its direct involvement in tumorigenesis or cancer
maintenance. It has been shown that the TNFRSF4 gene is hypomethylated in MDS CD34
+ cells [69] and a murine study has shown that expression of TNFRSF4 increases upon progres-
sion from MDS to AML [70].
In conclusion, we show that unsupervised clustering of the gene expression level of a large
set of apoptosis regulating genes does not identify gene signatures that are specific for MDS.
Moreover, when single genes were regarded, only a limited number of apoptosis-regulating
genes (BIK and TNFRSF4) were differentially expressed between normal and MDS derived
cell fractions. This does however not exclude a role for (dysregulated) apoptosis in the patho-
genesis of MDS, as we did not measure protein levels.
Methods
Patients and controls
We confirm that the study has been reviewed and approved by the Commissie Mensgebonden
Onderzoek (CMO), the institutional review board (IRB) at the Radboudumc (NL), with the
IRB file number CMO 2013/64 before the beginning of the study. For further details, contact
the CMO at commissiemensgebondenonderzoek@radboudumc.nl or at the phone number
0031-24-3613154. Bone marrow from MDS patients (n = 23) and healthy controls (n = 10) was
collected after informed consent. Written informed consent for the use of surplus diagnostic
patient material was obtained in compliance with institutional regulations. Patients diagnosed
at the Radboudumc belonging to all different WHO and IPSS categories were included. Patient
characteristics are shown in S1 Table. Patient 11 had an exceedingly high granulocyte count.
Nonetheless, the diagnosis of MDS RAEB1 was confirmed for this patient. All patient samples
were collected before treatment was administered. Mononuclear cells were isolated from the
bone marrow by density gradient centrifugation using Ficoll 1.077 g/mL (Pharmacia Biotech,
Uppsala, Sweden) and viably frozen in liquid nitrogen until further use.
Cell sorting and RNA isolation
After thawing, hematopoietic cell subtypes were isolated by fluorescence activated cell sorting
(FACS) using monoclonal antibodies directed against CD45 and the side scatter profile. In
addition, monoclonal antibodies directed against CD34, CD13, CD33 and CD71 were used.
Gating on forward and side scatter was used to exclude dead cells and debris. RNA was isolated
from three subfractions, the CD34+ stem/progenitor cells, the CD13/33+ mono/myeloid cells
and the CD71+ erythroid cells.
Gene expression analysis
In a first set of patients and controls, the expression of 180 different apoptosis-related genes
was measured simultaneously by real-time PCR employing a 384 Microfluidic Card (Applied
Biosystems). The genes measured and the corresponding assay numbers are shown in S2
Table. cDNA obtained from the CD34+ (patients n = 13, controls n = 5), CD71+ (patients
n = 12, controls n = 4) and CD13/33+ (patients n = 11, controls n = 5) cell fractions was ana-
lyzed. Based on the expression pattern of these genes, a selection of 93 genes was used to
Apoptotic Gene Expression Profile in MDS
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perform a similar expression analysis in an additional group of CD34+ (patients n = 8, controls
n = 5), CD71+ (patients n = 9, controls n = 5) and CD13/33+ cells (patients n = 8, controls
n = 5). The relative expression of the apoptosis-related genes was calculated by measuring the
housekeeping gene GAPDH. Relative expression values less than 1x10-6 were set to 1x10-6 to
avoid bias introduced by including values reaching the limit of detection of the real-time PCR
assay. In addition to the apoptosis-related genes, the expression of several genes implicated in
erythroid differentiation (TFRC, GYPA, GYPB, GYPC, SPTB, SPTA1, EBP41, EBP42 and HBB)
was determined to check whether these genes indeed showed highest expression in the CD71
+ cell fraction. The erythroid genes were only used as controls and not included in subsequent
statistical analyses. Complete data are retrievable on Gene Expression Omnibus with the acces-
sion number GSE89579.
Statistical analysis
Microfluidic card log-scale values were imported into Partek (Partek Genomic Suite software,
version 6.5; Partek Inc., St. Louis, MO). Principle Component Analysis (PCA) showed a clear
distinction between the three different tissues and thus the dataset was split accordingly into
three separate groups. In each group expression differences between donors and patients was
calculated using the non-parametric Mann-Whitney U-test. For statistical analysis, patients
from the IPSS low and int-1 risk groups were combined in a ‘low risk MDS’ group and patients
from the IPSS int-2 and high-risk groups in a ‘high-risk MDS’ group. Corresponding P-values
were corrected for multiple testing by random permutations. The Kruskall-Wallis-test was
used to identify differences between the ‘low risk MDS’, ‘high-risk MDS’ and control groups.
In case of a p-value< 0.05, posthoc analysis was performed using non-parametric Mann-Whit-
ney U test.
Supporting Information
S1 Table. Patients and controls. Patient characteristics: n/a = not available;  Normal Hemo-
globin (Hb) range in adults = 2.0–2.7 mmol/L in males, 1.8–2.5 mmol/L in females;  Normal
granulocyte absolute count range in adults = 1.3–8.0 x10^9. Depending on material availability
and quantity, it was possible to sort CD34+, CD71+, and CD13/33+ cell fractions from each
patient.
(DOCX)
S2 Table. Genes and assay numbers. Complete list of 384 apoptosis-related genes with Gene
symbols, RefSeq record, assay number, and assay replicate
(DOCX)
S3 Table. Differentially expressed genes. Genes with notable expression differences of
patients versus low-risk MDS versus high-risk MDS in A) in the CD34+, B) in the CD71+, and
C) in the CD13/33+ cell fraction.  indicates significant difference (p<0.05) in expression after
posthoc analysis.  indicates significant difference (p<0.05) using p-value for multiple testing.
(DOCX)
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